Muraglitazar and the FDA: what constitutes drug safety?

Prev Cardiol. 2006 Spring;9(2):110-4. doi: 10.1111/j.1520-037x.2000.5474.x.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Blood Glucose / drug effects
  • Databases, Factual
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy
  • Drug Approval*
  • Glycine / administration & dosage
  • Glycine / adverse effects
  • Glycine / analogs & derivatives*
  • Glycine / standards
  • Humans
  • Oxazoles / administration & dosage*
  • Oxazoles / adverse effects*
  • Oxazoles / standards
  • Peroxisome Proliferator-Activated Receptors / adverse effects*
  • Peroxisome Proliferator-Activated Receptors / agonists*
  • Peroxisome Proliferator-Activated Receptors / standards
  • Randomized Controlled Trials as Topic
  • United States
  • United States Food and Drug Administration*

Substances

  • Blood Glucose
  • Oxazoles
  • Peroxisome Proliferator-Activated Receptors
  • Glycine
  • muraglitazar